A Wealth of Experience

We have collaborated with our clients on projects to research liver disease, liver treatment, and complications and comorbidities of liver disease. Our experience includes:

  • Acute Liver Failure
  • Hepatitis Infection
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C
  • Hepatoxicity
  • Liver Steatosis
  • Thrombocytopenia in chronic hepatitis C

Types of Projects

We have implemented studies to help our clients develop strategies in the hepatic market and to develop and gain market access for products to treat liver disease and complications arising from treatment of liver disease.

Recent projects have included:

Our Experts

Sorrel Wolowacz
Head, European Health Economics
Annete Njue
Director, Market Access and Outcomes Strategy
Isobel Pearson
Director, Health Economics, Health Technology Assessment
Xiaolei Zhou
Director, Biostatistics
Josephine Mauskopf
Vice President, Health Economics
Keith Davis
Head, Health Economics
Kati Copley-Merriman
Vice President, Market Access and Outcomes Strategy
Caroline Ling
Senior Director and HTA Specialist Market Access and Outcomes Strategy

Selected Recent Hepatic Publications

Pladelvall M, Pottegard A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Kollhorst B, Brandt L, Cortes J, Aguado J, Perlemuter G, Falissard B, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a post authorisation safety study (PASS) in four European countries. Poster presented at the 31st ECNP Congress; October 8, 2018. Barcelona, Spain.